Novartis presents new data on safety and efficacy of Zolgensma
Novartis today presented new data that continue to support the clinical benefits of Zolgensma® (onasemnogene abeparvovec), the only one-time gene therapy for the treatment of spinal muscular atrophy (SMA). Final data from the SMART study highlight the safety and efficacy profile of Zolgensma in children with SMA weighing ≥ 8.5 kg to ≤ 21 kg, with a mean age of 4.69 years, most of whom (21/24, 87.5%) had discontinued use of another disease modifying therapy at the time of treatment. (Source: World Pharma News)
Source: World Pharma News - March 4, 2024 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Cleveland Clinic researchers uncover how virus causes cancer, point to potential treatment
Cleveland Clinic researchers have discovered a key mechanism used by Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), to induce cancer. The research points to effective new treatment options for KSHV-associated cancers, including Kaposi's sarcoma, primary effusion lymphoma, and HHV8-associated multicentric Castleman disease. (Source: World Pharma News)
Source: World Pharma News - March 1, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Pfizer announces positive top-line data for full season two efficacy of ABRYSVO ® for RSV in older adults
Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iNOlder adults Immunized against RSV disease). (Source: World Pharma News)
Source: World Pharma News - February 29, 2024 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Anti-cancer drug could improve symptoms after stroke
A study by the Institut de Neurociències of the UAB (INc-UAB) demonstrates in animal models the benefits of vorinostat after having suffered a stroke. The drug, used in humans to treat cutaneous T-cell lymphoma, has been proved to mitigate brain injuries and help in restoring brain tissue.
Ischemic stroke is the second leading cause of death worldwide and occurs when blood flow cannot reach the brain due to an obstruction. (Source: World Pharma News)
Source: World Pharma News - February 28, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Bayer receives U.S. FDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations
Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for BAY 2927088 for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have received a prior systemic therapy. BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), (Source: World Pharma News)
Source: World Pharma News - February 27, 2024 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Innovative chemotherapy approach shows promise against lung cancer
Lung cancer is not the most common form of cancer, but it is by far the deadliest.
Despite treatments such as surgery, radiation therapy and chemotherapy, only about a quarter of all people with the disease will live more than five years after diagnosis, and lung cancer kills more than 1.8 million people worldwide each year, according to the World Health Organization. (Source: World Pharma News)
Source: World Pharma News - February 26, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
European Commission approves Pfizer & #039;s VELSIPITY ® for patients with moderately to severely Active ulcerative colitis
Pfizer Inc. (NYSE: PFE) announced that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent. (Source: World Pharma News)
Source: World Pharma News - February 23, 2024 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Researchers find possible solutions to reverse Alzheimer & #039;s Disease impact
University of North Carolina at Chapel Hill researchers have developed a new drug delivery platform that harnesses helical amyloid fibers designed to untwist and release drugs in response to body temperatures.
A new research paper published on Jan. 26 in Nature Communications reveals groundbreaking structural details into how diseases form much like Alzheimer's disease. (Source: World Pharma News)
Source: World Pharma News - February 22, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Researchers use machine learning to predict how ingested drugs will interact with transport proteins
Before orally administered drugs can make their way throughout the body, they must first bind to membrane proteins called drug transporters, which carry compounds across the intestinal tract and help them reach their intended targets. But because one drug can bind to several different drug transporters, they may struggle to get past this gut barrier, potentially leading to decreased drug absorption and efficacy. (Source: World Pharma News)
Source: World Pharma News - February 21, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New model identifies drugs that shouldn ’t be taken together
Any drug that is taken orally must pass through the lining of the digestive tract. Transporter proteins found on cells that line the GI tract help with this process, but for many drugs, it’s unknown which of those transporters they use to exit the digestive tract.
Identifying the transporters used by specific drugs could help to improve patient treatment because if two drugs rely on the same transporter, they can interfere with each other and should not be prescribed together. (Source: World Pharma News)
Source: World Pharma News - February 20, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Acquisition of Icosavax completed
AstraZeneca announced today the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical company focused on developing differentiated, high-potential vaccines using an innovative, protein virus-like particle (VLP) platform. As a result of the acquisition, Icosavax has become a subsidiary of AstraZeneca, with operations in Seattle, US. (Source: World Pharma News)
Source: World Pharma News - February 19, 2024 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
UIC research helps create new antibiotic that evades bacterial resistance
Scientists at the University of Illinois Chicago and Harvard University have developed an antibiotic that could give medicine a new weapon to fight drug-resistant bacteria and the diseases they cause.
The antibiotic, cresomycin, described in Science, effectively suppresses pathogenic bacteria that have become resistant to many commonly prescribed antimicrobial drugs. (Source: World Pharma News)
Source: World Pharma News - February 16, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002 (also known as NAN-101) for the treatment of congestive heart failure (CHF). (Source: World Pharma News)
Source: World Pharma News - February 15, 2024 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Clinical trial shows rheumatoid arthritis drug could prevent disease
A drug used to treat rheumatoid arthritis could also prevent the disease in individuals deemed to be at risk.
Results from a Phase 2b clinical trial, published in The Lancet by researchers led by King's College London, provides hope for arthritis sufferers after it was shown that the biologic drug abatacept reduces progression to this agonising chronic inflammatory disease. (Source: World Pharma News)
Source: World Pharma News - February 14, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Cleveland Clinic research reveals unique tumor-related bacteria tied to young-onset colorectal cancer
New research from global health system Cleveland Clinic has mapped changes in tumor-related bacteria to uncover potential new strategies to combat the rise of young-onset colorectal cancer (CRC) in people under the age of 50.
The research reveals differences in tumor-related bacteria associated with young-onset colorectal cancer. (Source: World Pharma News)
Source: World Pharma News - February 13, 2024 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
